在HER2阳性乳腺癌中开发具有强大抗瘤功效的基于埃克萨特干的优化免疫结合剂
Etienne Auvert1, Emmanuel Douez2,3, Louis Jolivet4
1UMR 1100, Research Center for Respiratory Diseases (CEPR), Team Proteolytic enzymes and their pharmacological targeting in lung diseases, University of Tours, Inserm, F-37032 Tours, France.
Journal of medicinal chemistry
|September 5, 2025
概括
针对HER2阳性乳腺癌的新抗体药物结合剂显示出强烈的疗效. 这些新疗法,IgG(8) -EXA和Mb(4) -EXA,为现有治疗提供了有前途的替代方案,并提高了安全性.
科学领域:
- 癌症学
- 药理学
- 生物结合化学
背景情况:
- 人类表皮生长因子受体2 (HER2) 阳性乳腺癌的治疗已通过抗体与药物联合剂 (ADC) 取得进展.
- 特拉斯图祖马布德鲁克斯坦 (T-DXd) 是一个突出的抗药剂,它面临着挑战,包括可能与Fcγ受体相互作用相关的耐药性和不良反应.
- 需要新的ADC设计来克服当前治疗的局限性.
研究的目的:
- 开发新的针对HER2的抗体药物合物 (ADC),使用exatecan,一个坎普托西因衍生物.
- 设计链接技术以优化疏水性和药物对抗体比 (DAR).
- 评估新的ADC形式的疗效和药物动力学特征.
主要方法:
- 三种针对HER2的新型结合物的合成和表征:IgG(8) -EXA (基于高达尔IgG),Mb(4) -EXA (无达尔4Fc) 和Db(4) -EXA (无达尔4Fc).
- 对HER2阳性乳腺癌细胞的体内细胞毒性评估.
- 在体内抗瘤活性和药物动力学的评估.
主要成果:
- 针对HER2阳性乳腺癌细胞,IgG(8)-EXA和Mb(4)-EXA具有强大和特异性细胞毒性.
- 在临床前模型中,IgG(8) - EXA和Mb(4) - EXA都表现出显著的抗瘤活性.
- 即使药物对抗体比率很高,IgG(8)-EXA也表现出良好的药理学特征.
结论:
- 新的IgG(8) -EXA和Mb(4) -EXA对HER2阳性乳腺癌具有有前途的治疗候选.
- 优化药物链接器设计可以提高ADC的有效性,并可能减轻不良影响.
- 这些结合物的进一步临床前开发是有必要的.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.9K
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.7K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
01:30Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K